Rapamycin Resistant Murine Th9 Cells Have a Stable In Vivo Phenotype and Inhibit Graft-Versus-Host Reactivity

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Mangus, Courtney W ^a,b   Massey, Paul R ^a   Fowler, Daniel H ^a   Amarnath, Shoba ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 4; INTERLEUKIN 9; RAPAMYCIN; TRANSFORMING GROWTH FACTOR BETA;

ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TRANSPLANTATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL LINEAGE; CELL THERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; ENGRAFTMENT; ENZYME ACTIVITY; ENZYME INHIBITION; GRAFT VERSUS HOST REACTION; IN VIVO STUDY; MOUSE; NONHUMAN; PHENOTYPE; PLASTICITY; T LYMPHOCYTE; TH2 CELL; TH9 CELL; TREATMENT RESPONSE;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL POLARITY; GRAFT VS HOST DISEASE; INTERLEUKIN-4; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PHENOTYPE; SIROLIMUS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84882676700     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072305     Document Type: Article

References (25)

1. Veldhoen M, Uyttenhove C, van Snick J, Helmby H, Westendorf A, et al. (2008) Transforming growth factor-beta 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat Immunol 9: 1341-1346.
2. Gessner A, Blum H, Rollinghoff M, (1993) Differential regulation of IL-9-expression after infection with Leishmania major in susceptible and resistant mice. Immunobiology 189: 419-435.
3. Dardalhon V, Awasthi A, Kwon H, Galileos G, Gao W, et al. (2008) IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells. Nat Immunol 9: 1347-1355.
4. Khan WI, Richard M, Akiho H, Blennerhasset PA, Humphreys NE, et al. (2003) Modulation of intestinal muscle contraction by interleukin-9 (IL-9) or IL-9 neutralization: correlation with worm expulsion in murine nematode infections. Infect Immun 71: 2430-2438.
5. Cheng G, Arima M, Honda K, Hirata H, Eda F, et al. (2002) Anti-interleukin-9 antibody treatment inhibits airway inflammation and hyperreactivity in mouse asthma model. Am J Respir Crit Care Med 166: 409-416.
6. Nicolaides NC, Holroyd KJ, Ewart SL, Eleff SM, Kiser MB, et al. (1997) Interleukin 9: a candidate gene for asthma. Proc Natl Acad Sci U S A 94: 13175-13180.
7. Wilhelm C, Hirota K, Stieglitz B, Van Snick J, Tolaini M, et al. (2011) An IL-9 fate reporter demonstrates the induction of an innate IL-9 response in lung inflammation. Nat Immunol 12: 1071-1077.
8. Poulin LF, Richard M, Le Moine A, Kiss R, McKenzie AN, et al. (2003) Interleukin-9 promotes eosinophilic rejection of mouse heart allografts. Transplantation 76: 572-577.
9. Lu Y, Hong S, Li H, Park J, Hong B, et al. (2012) Th9 cells promote antitumor immune responses in vivo. J Clin Invest 122: 4160-4171.
10. Lu LF, Lind EF, Gondek DC, Bennett KA, Gleeson MW, et al. (2006) Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 442: 997-1002.
11. Sabers CJ, Martin MM, Brunn GJ, Williams JM, Dumont FJ, et al. (1995) Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem 270: 815-822.
12. Battaglia M, Stabilini A, Migliavacca B, Horejs-Hoeck J, Kaupper T, et al. (2006) Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol 177: 8338-8347.
13. Amarnath S, Costanzo CM, Mariotti J, Ullman JL, Telford WG, et al. (2010) Regulatory T cells and human myeloid dendritic cells promote tolerance via programmed death ligand-1. PLoS Biol 8: e1000302.
14. Jung U, Foley JE, Erdmann AA, Toda Y, Borenstein T, et al. (2006) Ex vivo rapamycin generates Th1/Tc1 or Th2/Tc2 Effector T cells with enhanced in vivo function and differential sensitivity to post-transplant rapamycin therapy. Biol Blood Marrow Transplant 12: 905-918.
15. Amarnath S, Flomerfelt FA, Costanzo CM, Foley JE, Mariotti J, et al. (2010) Rapamycin generates anti-apoptotic human Th1/Tc1 cells via autophagy for induction of xenogeneic GVHD. Autophagy 6: 523-541.
16. Amarnath S, Chen H, Foley JE, Costanzo CM, Sennesh JD, et al. (2011) Host-based Th2 cell therapy for prolongation of cardiac allograft viability. PLoS One 6: e18885.
17. Foley JE, Jung U, Miera A, Borenstein T, Mariotti J, et al. (2005) Ex vivo rapamycin generates donor Th2 cells that potently inhibit graft-versus-host disease and graft-versus-tumor effects via an IL-4-dependent mechanism. J Immunol 175: 5732-5743.
18. Mariotti J, Foley J, Ryan K, Buxhoeveden N, Kapoor V, et al. (2008) Graft rejection as a Th1-type process amenable to regulation by donor Th2-type cells through an interleukin-4/STAT6 pathway. Blood 112: 4765-4775.
19. Mariotti J, Foley J, Jung U, Borenstein T, Kantardzic N, et al. (2008) Ex vivo rapamycin generates apoptosis-resistant donor Th2 cells that persist in vivo and prevent hemopoietic stem cell graft rejection. J Immunol 180: 89-105.
20. Fowler DH, Mossoba ME, Steinberg SM, Halverson DC, Stroncek D, et al. (2013) Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation. Blood 121: 2864-2874.
21. Amarnath S, Fowler DH, (2012) Harnessing autophagy for adoptive T-cell therapy. Immunotherapy 4: 1-4.
22. Laurence A, Amarnath S, Mariotti J, Kim YC, Foley J, et al. (2012) STAT3 transcription factor promotes instability of nTreg cells and limits generation of iTreg cells during acute murine graft-versus-host disease. Immunity 37: 209-222.
23. Amarnath S, Mangus CW, Wang JC, Wei F, He A, et al. (2011) The PDL1-PD1 axis converts human TH1 cells into regulatory T cells. Sci Transl Med 3: 111ra120.
24. Tan C, Gery I, (2012) The unique features of Th9 cells and their products. Crit Rev Immunol 32: 1-10.
25. Tan C, Aziz MK, Lovaas JD, Vistica BP, Shi G, et al. (2010) Antigen-specific Th9 cells exhibit uniqueness in their kinetics of cytokine production and short retention at the inflammatory site. J Immunol 185: 6795-6801.